SG Americas Securities
ATNM icon

SG Americas Securities’s Actinium Pharmaceuticals ATNM Stock Holding History

SG Americas Securities’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11,513
Closed -$15K – 3477
2024
Q4 		$15K Buy
+11,513
New +$17.9K ﹤0.01% 3028
2014
Q4 		– Sell
-381
Closed -$77K – 3165
2014
Q3 		$77K Buy
+381
New +$75.6K ﹤0.01% 2419

Other funds holding ATNM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Los Angeles Capital Management
Los Angeles Capital Management Los Angeles, California $25.4B AUM 38.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

SG Americas Securities's ATNM Position: Q1 2025 in Review

SG Americas Securities sold out of Actinium Pharmaceuticals (ATNM) in Q1 2025, closing a stake of 11,513 shares — an estimated $15K sold.

SG Americas Securities first reported a position in ATNM in Q3 2014 and held it in 2 quarters. The position peaked at $77K in Q3 2014. 69 funds tracked by Wall St. Rank hold ATNM as of Q1 2025.

  • SG Americas Securities reported no remaining Actinium Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • SG Americas Securities sold 11,513 Actinium Pharmaceuticals shares in Q1 2025, an estimated $15K.
  • SG Americas Securities first reported a position in Actinium Pharmaceuticals in Q3 2014 and held it in 2 quarters.
  • SG Americas Securities's Actinium Pharmaceuticals position peaked at $77K in Q3 2014.
  • 69 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2025.

Based on SG Americas Securities's 13F filing for Q1 2025, filed 15 Apr 2025.